Emergent BioSolutions (EBS) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed Emergent BioSolutions (EBS) over the past year, gaining 63.3% versus a loss of 28.7%. Over five years, EBS leads with a -86.1% price change compared with -86.2% for RLMD. Emergent BioSolutions is the larger company by market cap ($362.5 million vs $346.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | RLMD |
|---|---|---|
| Share price | $7.07 | $3.25 |
| Market cap | $362.50M | $346.68M |
| 1-day change | +1.73% | -0.91% |
| YTD return | -42.80% | -32.71% |
| 1-year return | -28.73% | +63.32% |
| 5-year return | -86.05% | -86.25% |
| Forward P/E | 6.76 | — |
| EPS (TTM) | $-3.40 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.06 | $8.00 |
| 52-week low | $4.36 | $1.80 |
| Distance from 52-week high | -49.72% | -59.38% |
| Average volume | 1.16M | 1.34M |
| Shares outstanding | 51.27M | 106.67M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed EBS by 92.0 percentage points over the past year.
EBS vs RLMD FAQ
Which is bigger, Emergent BioSolutions or Relmada Therapeutics?
Emergent BioSolutions (EBS) is larger, with a market capitalization of $362.50M compared with $346.68M for Relmada Therapeutics (RLMD).
Which stock has performed better over the past year, EBS or RLMD?
RLMD returned +63.32% over the past 12 months, compared with -28.73% for EBS (price return, excluding dividends). Past performance does not predict future results.
Are Emergent BioSolutions and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.